CERo Therapeutics (CERO) announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. The trial is focused on patients with acute myeloid leukemia, and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025. The trial will be led by Abhishek Maiti, M.D., assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Chris Ehrlich, CERo Therapeutics CEO added, “It is encouraging to conduct our trial at one of the most renowned cancer centers in the United States, which we believe is a validation of the scientific work performed to date with CER-1236. The assignment of clinical trial sites is an important milestone. We look forward to announcing enrollment and first dosing in the near term.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Delays Yearly Report Filing
- Cero Therapeutics receives FDA clearance of second IND application for CER-1236
- Cero Therapeutics set to initiate enrollment of Phase 1 trial of CER-1236
- CERo enters manufacturing agreement with University of California Davis
- Cero Therapeutics presents preclinical data on CER-1236 at SITC Spring meeting